$11 billion drugmaker Mylan and US drug giant Pfizer are teaming up to reshape Mylan’s business. 3 tough questions from Wall Street analyst show the challenging road ahead.

📆 7/29/2019 2:48 PM
📰 BusinessInsider

⏱ Reading Time:
18 sec. here
2 min. at publisher
📊 Quality Score:
News: 11%
Publisher: 51%

United States News News

United States United States Latest News,United States United States Headlines

Wall Street analysts asked big questions about the new company's future. Execs occasionally got testy.

Three tough questions from Wall Street analysts on a Monday conference call show why the spinoff could face an uphill battle.

A major deal announced on Monday will combine generic drugmaker Mylan with a unit of Pfizer that makes off-patent products like Viagra., best known for making the EpiPen allergy shot. Mylan's shares have lost almost half their value over the past year, though they surged 14% on Monday after the deal was announced. Pfizer's stock fell 2%.

Write Comment

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

United States United States Latest News, United States United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Fewer investors have a 'fear of missing out,' so it may be time to buckle up, market bull suggestsOppenheimer Asset Management's John Stoltzfus expects wave of volatility to pressure stocks due to uncertainty. FuturesNow ohh it's going to be a a good dump for sure!
Source: CNBC - 🏆 12. / 72 Read more »